Clinical Trial Update: Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis [Phase 1, Phase 2]

View source ↗

Summary

The document reports the completion of Phase 1 and Phase 2 trials of ARO-MMP7 Inhalation Solution in healthy subjects and patients with Idiopathic Pulmonary Fib…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• ARO-MMP7 Inhalation Solution (Matrix metalloproteinase-7 inhibitor)

Snippet

Sponsor: Arrowhead Pharmaceuticals | Conditions: Idiopathic Pulmonary Fibrosis | Phase 1, Phase 2 | Status: COMPLETED